StockWatch
·
Medical Specialities
Quarterly ResultJul 28, 2026, 06:08 AM

Centene Q2 Net Earnings $1.09B; EPS $2.19; Revenue $53.58B

AI Summary

Centene reported a strong second quarter 2026, with GAAP net earnings of $1.09 billion, a significant improvement from a loss in the prior year period. Diluted EPS reached $2.19, and total revenues increased to $53.58 billion. The company also highlighted the ongoing divestment of Magellan Health and the sale of $1 billion in Part D receivables.

Key Highlights

  • Q2 2026 GAAP Net Earnings attributable to Centene: $1,091 million, up from $(253) million loss in Q2 2025.
  • Q2 2026 GAAP Diluted EPS attributable to Centene: $2.19, up from $(0.51) loss in Q2 2025.
  • Q2 2026 Total Revenues: $53,579 million, an increase from $48,742 million in Q2 2025.
  • YTD 2026 Net Cash Provided by Operating Activities: $7,956 million, up from $3,295 million in YTD 2025.
  • Divestment of Magellan Health: $293 million in assets and liabilities held for sale as of June 30, 2026.
  • Sale of Part D receivables: $1,000 million sold in March 2026, generating $970 million net cash.
  • Cash and cash equivalents as of June 30, 2026: $24,151 million.